HOME >> BIOLOGY >> NEWS
UCLA engineering and Mattel Children's Hospital collaborate to develop children's heart valve

Children with congenital heart defects may soon have an alternative to invasive open heart surgery that will mean less time in the hospital, a quicker recovery and no need to break open the breastbone, thanks to a new collaboration between researchers at the UCLA Henry Samueli School of Engineering and Applied Science and pediatric cardiologists at Mattel Children's Hospital at UCLA.

Using a super-elastic, shape-memory metal alloy called "thin film nitinol," UCLA engineers are developing a collapsible heart valve for children that can be loaded into a catheter, inserted into a vein in the groin area, guided into place and then deployed in a precise location within the heart. As the valve is released from the catheter, it springs back to its original shape and begins to function.

"What is really novel about the valve UCLA Engineering has created is the memory retaining alloy and butterfly design that opens or hinges from the middle of the valve rather than the edges," said UCLA mechanical and aerospace engineering professor Gregory Carman, who, along with UCLA researcher Lenka Stepan, crafted the valve. "The unobtrusive leaflets within the valve mean there is no obstruction to blood flow. This smaller, low-profile design is well suited for children and, over time, will potentially allow children born with heart valve defects to experience less pain and live much fuller lives."

Dr. Daniel Levi, assistant professor of pediatric cardiology at Mattel Children's Hospital at UCLA, designed the valve and joined Carman and Stepan to create and develop the revolutionary new device.

"Using catheters and collapsible valves, heart valves can be replaced without stopping the heart, without cutting the chest open and without long recovery times," Levi said. "This will represent a huge improvement in care for children living with a very difficult condition."

A defective heart valve fails to fully open or close, letting blood leak back into th
'"/>

Contact: Melissa Abraham
mabraham@support.ucla.edu
310-206-0540
University of California - Los Angeles
13-Feb-2006


Page: 1 2 3

Related biology news :

1. New UD tissue-engineering research focuses on vocal cords
2. Small, self-controlled planes combine plant pathology and engineering
3. FSU engineering professor growing bone in a lab
4. UC engineering researchers uncover factors that control ion motion in solid electrolytes
5. UD scientist wins NSF career award for tissue engineering research
6. New success in engineering plant oils
7. Bioengineering efficient antibiotic biosynthesis in E. coli
8. More women students choose engineering -- but not as a career
9. Bioengineer wins $500,000 engineering prize
10. Researchers to present advances in energy, health, technology at chemical engineering conference
11. Research Council feted NJIT chemical engineering professor

Post Your Comments:
(Date:5/21/2013)... largest gathering of biomass experts , Where? ... When? 03-07 June 2013 , ... research, resource assessment, market and policy developments, manufacturing and ... world and benefiting from its 2013 edition from a ... than 60 countries, more than 240 plenary and oral ...
(Date:5/21/2013)... epigenetic modifications, which alter the way genes function ... be detected in the blood of pregnant women ... to foretell depression in the weeks after giving ... become debilitating. , The findings of the small ... in the journal Molecular Psychiatry . , ...
(Date:5/20/2013)... the effect of physical education (PE) on child weight, ... increasing the amount of time that elementary schoolchildren spent ... The study represents some of the first evidence of ... is forthcoming in the Journal of Health Economics ... can be viewed at: http://www.sciencedirect.com/science/article/pii/S0167629613000556 , The ...
Breaking Biology News(10 mins):21st European Biomass Conference and Exhibition 221st European Biomass Conference and Exhibition 321st European Biomass Conference and Exhibition 4Genetic predictors of postpartum depression uncovered by Hopkins researchers 2Genetic predictors of postpartum depression uncovered by Hopkins researchers 3Gym class reduces probability of obesity, study finds for first time 2
(Date:5/21/2013)... Wisc. (PRWEB) May 21, 2013 ... parts distributor , will be exhibiting for the ... Advancement of Medical Instrumentation (AAMI) 2013 Conference and ... purchase, support, distribute, and manufacture healthcare technologies. This ... in Long Beach, California. , The three-day ...
(Date:5/21/2013)... NC (PRWEB) May 21, 2013 ... financial services company for clinical trials, announced today ... Spend Solutions, LLC. Clinverse’s ClinPay® FLS eClinical ... investigator payment process. SpendMD ™, Aggregate ... complete solution for tracking and reporting transfer of ...
(Date:5/21/2013)... Canada (PRWEB) May 21, 2013 ... is a strong push within the industry to ... and Manufacturing Organizations and pharma companies often means ... frames. , Microtablets, developed in collaboration with Sensidose ... effective outsourcing can bring products to market sooner. ...
(Date:5/21/2013)... , May 21, 2013  MacroGenics, Inc. today ... of margetuximab (MGAH22), an Fc-modified chimeric monoclonal antibody ... the HER2 oncoprotein," will be presented at the ... Clinical Oncology during the Developmental Therapeutics - Immunotherapy ... 4:15 – 4:30 PM.  The presentation will describe ...
Breaking Biology Technology:Alpha Source, Inc. to Exhibit at the AAMI 2013 Conference and Expo 2Clinverse, Inc. Announces Strategic Alliance with Aggregate Spend Solutions, LLC 2Clinverse, Inc. Announces Strategic Alliance with Aggregate Spend Solutions, LLC 3The Development of an Innovative Microtablet Dosage Form, a Success Story: Live Webinar Hosted by Xtalks 2MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 2MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 3
Cached News: